Clearmind Medicine Inc.

Stage 4 · Declining · week 51

As of Oct 22, 2026, Clearmind Medicine is in Stage 4, the downtrend phase, now in week 51 (since Oct 17, 2025). It closed at $6.00, 99.8% below its 52-week high and below its 200-day average, which is falling.

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. More about the company

$6.00

+1.01% today

$3.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CMND early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 43w

S2 16w

S4 20w

S4 53w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 2w → S4 43w → S1 11w → S4 6w → S1 2w → S2 16w → S3 1w → S4 20w → S1 11w → S4 53w current

Total tracked: 166 weeks across 10 stage runs.

CMND among Biotechnology552nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…552	CMNDClearmind Medicine Inc.	Stage 4 · wk 51	2	−11.8%

vs 52W High

-99.8%

$5.72 lo$3,232.00 hi

99.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 51

1w13w26w

Week 51, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-88.8%

200 DMA: $53.48 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.07x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-11.8%

-53.4%

-90.8%

YTD

-96.2%

-99.8%

Scan Membership

Breakout Watch

Latest: 2024-11-12

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 51 · Vol 0.07x

2026-10-21S4

Wk 51 · Vol 0.07x

2026-10-20S4

Wk 51 · Vol 0.10x

2026-10-19S4

Wk 51 · Vol 0.12x

2026-10-16S4

Wk 51 · Vol 0.05x

2026-10-15S4

Wk 50 · Vol 0.08x

2026-10-14S4

Wk 50 · Vol 0.15x

2026-10-13S4

Wk 50 · Vol 0.15x

2026-10-12S4

Wk 50 · Vol 0.22x

2026-10-09S4

Wk 50 · Vol 0.12x

2026-10-08S4

Wk 49 · Vol 0.57x

2026-10-07S4

Wk 49 · Vol 2.09x

Moving averages & range

50 DMA

$9.15

200 DMA

$53.48

52W High

$3,232.00

52W Low

$5.72

5D Low

$5.94

Resistance levels (recent highs)

20d High

$6.60

60d High

$15.68

120d High

$54.00

250d High

$3,232.00

Next resistance

+10.0%

to 20d High

ROE

-107.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.1

Clearmind Medicine: quick answers

What stage is Clearmind Medicine in?

As of Oct 22, 2026, Clearmind Medicine (CMND) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 17, 2025 and is in week 51. What the four stages mean

Is Clearmind Medicine in an uptrend?

No. Clearmind Medicine is in a Stage 4 downtrend. It trades 88.8% below its 200-day average, which is falling.

How far is Clearmind Medicine from its 52-week high?

Clearmind Medicine closed at $6.00 on Oct 22, 2026, 99.8% below its 52-week high of $3,232.00. Its 52-week low is $5.72.

How has Clearmind Medicine performed over the past year?

As of Oct 22, 2026, Clearmind Medicine is down 99.8% over the past year and down 96.2% so far in 2026.

Which sector and industry is Clearmind Medicine in?

Clearmind Medicine is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.